松龄血脉康联合长春西汀治疗脑梗死后遗症临床观察

发布时间：2018-10-08 16:24

【摘要】：目的:观察松龄血脉康联合长春西汀改善脑梗死后遗症的神经功能受损状态、日常行为能力和血流变相关指标的效果及其安全性。方法:观察组47例,每日静脉滴注长春西汀1次(30 mg长春西汀加入500m L0.9NS静脉滴注),共用14 d,停用长春西汀后改为口服松龄血脉康胶囊,每日3次,每次1.5 g,共用3月;对照组给予长春西汀注射液静滴,用药方法同前。结果:松龄血脉康联合长春西汀的观察组神经功能缺损、日常行为能力改善情况、总有效率(82.98%)优于单用长春西汀的对照组(总有效率59.52%);观察组治疗后血流变各指标明显改善;对照组治疗后纤维蛋白原低于治疗前,其余血流变指标指标均无明显变化;两组在治疗期间,均未发现明显不良反应。结论:松龄血脉康联合长春西汀可以有效改善脑梗死后遗症神经功能缺损,提高日常生活活动能力,改善血流变各项指标,具有较好的药物协同作用。
[Abstract]:Aim: to observe the effect and safety of Songling Xuemaikang combined with vinpocetine in improving neurological function, daily behavior and hemorheological parameters in patients with cerebral infarction sequelae. Methods: 47 patients in the observation group were treated with vinpocetine once a day (30 mg vinpocetine plus 500m L0.9NS intravenous drip) for 14 days. After taking vinpocetine for 14 days, Songling Xuemaikang capsule was taken orally 3 times a day, 1.5 g each time for 3 months. The control group was treated with vinpocetine injection by intravenous drip. Results: the total effective rate of the observation group (82.98%) was better than that of the control group (59.52%). After treatment, the fibrinogen in the control group was lower than that before treatment, but the other hemorheological indexes had no significant change, and no significant adverse reactions were found in the two groups during the treatment period. Conclusion: Songling Xuemaikang combined with vinpocetine can effectively improve the neurological function defect of sequelae of cerebral infarction, improve the activity of daily life, and improve the indexes of hemorheology.
【作者单位】：温州医科大学附属第一医院神经内一科;
【基金】：温州市科技局项目(Y20120154)
【分类号】：R743.33

【相似文献】